Adcock Ingram Critical Care
Exclusive distribution for South Africa and ten additional Sub-Saharan African countries. The January 2026 agreement covers Gefena and Nimorazole.
Partnership detailsAbout us
Local roots. Global perspective.
AFYX Therapeutics is a Danish biopharmaceutical company focused on reformulation and repurposing of pharmaceuticals.
Making our presence felt worldwide
Reaching 46 markets with trusted partners.
AFYX reports a presence in 46 global markets, through direct operations and valued commercial partners.
Our work spans head and neck cancer, labour induction, cluster headache, and pain and addiction. We bring together experience in research, development, manufacturing and commercialization.
Our partner network
Working together across markets.
We collaborate with distribution partners to connect established medicines with healthcare systems in local markets.
Er-Kim
Sales and distribution for Gefena and Nimox across 22 markets in Central, Eastern and Southern Europe, the Balkans and Turkey.
Partnership detailsLunatus
Distribution and commercialization of Gefena in the UAE, Qatar, Kuwait, Oman, Saudi Arabia, Bahrain, Iraq and Jordan.
Partnership detailsCevidra
French market partner for AFYX’s head and neck cancer portfolio, with local pharmaceutical, market-access and distribution expertise.
Partnership detailsMerging decades of technology
Different beginnings. One shared purpose.
AFYX Therapeutics was formed by bringing together companies with complementary experience in drug delivery, pain and cancer research, and pharmaceutical development.
AFYX Therapeutics
Developed a patented patch technology designed to adhere to wet surfaces.
Lionheart Pharmaceuticals
Focused on treatment approaches for chronic and intermittent cluster headache.
Inphena Pain & Cancer
Research, development and sales of repurposed existing pharmaceuticals.
AFYX merger
The organizations combined, building a company with a history of reversed innovation.
Our purpose
Improve lives through a different perspective.
We work to address unmet medical needs by rethinking what proven technologies can do.
